What is the standard of care for metastatic Pancreatic Cancer according to NCCN guidelines

Standard of Care for Metastatic Pancreatic Cancer (NCCN Guidelines)

Based on the NCCN Guidelines Version 2.2025 for Pancreatic Adenocarcinoma, here's what the standard approach includes:

Initial Workup & Testing

When metastatic pancreatic cancer is diagnosed, your care team should:

Diagnostic confirmation:

• Obtain a biopsy (preferably from a metastatic site) to confirm adenocarcinoma
• Complete staging with chest and pelvis CT scans
• Perform genetic testing for inherited mutations (looking for BRCA1/2, PALB2, ATM, and other hereditary cancer genes)
• Conduct molecular profiling of tumor tissue using next-generation sequencing (NGS) to identify actionable mutations

According to NCCN Guidelines, molecular profiling should look for:

• KRAS mutations (present in ~87% of pancreatic cancers)
• BRCA1/2 mutations
• Mismatch repair deficiency (dMMR)
• Microsatellite instability (MSI)
• Other emerging alterations (BRAF, HER2, NTRK, ROS1, FGFR2, RET fusions)

---

First-Line Treatment Approach

The treatment pathway depends on your performance status (how well you're functioning):

For Patients with Good or Intermediate Performance Status:

Clinical trials are PREFERRED as the first option, followed by:

• Systemic chemotherapy (standard cytotoxic chemotherapy regimens)
• Targeted therapy or immunotherapy based on your molecular profiling results
• Palliative radiation therapy if you have severe pain not controlled by medications

For Patients with Poor Performance Status:

• Palliative and best supportive care
• Consider single-agent chemotherapy if appropriate
• Possibly targeted therapy based on molecular profiling

---

Important Considerations During Treatment

Biliary obstruction management: If jaundice (yellowing of skin/eyes) is present, placement of a self-expanding metal stent (SEMS) via ERCP (endoscopic procedure) is recommended.

Maintenance therapy: After 4-6 months of chemotherapy with acceptable tolerance and no disease progression, options include:

• Continued chemotherapy
• Metastasis-directed therapy at a high-volume center (in select cases with limited disease)
• Clinical trials
• Chemotherapy holiday (planned break)

---

Treatment After Disease Progression

If your cancer progresses on initial therapy, NCCN Guidelines recommend:

Within 6 months of completing primary therapy:

• Clinical trials (preferred)
• Repeat the same systemic therapy
• Alternate systemic therapy not previously used
• Palliative and best supportive care

6 or more months after completing primary therapy:

• Switch between chemotherapy types (if you received gemcitabine-based therapy, switch to fluoropyrimidine-based, or vice versa)
• Alternate systemic therapy
• Clinical trials
• Palliative and best supportive care

---

Key Points About Precision Medicine

According to Dr. [removed] Strickler's insights from the Cancer Patient Lab webinar on "Navigating Pancreatic Cancer," the field is entering an era of precision cancer medicine for pancreatic cancer:

• Every pancreatic cancer patient should ask their doctor: "Have you done molecular profiling on my cancer? Can I see the report?"
• Molecular profiling results typically live outside the standard medical chart, so keep a printed copy with you
• New KRAS-targeting drugs are becoming available and represent a major shift away from traditional chemotherapy alone
• Cancer vaccines are in early clinical trials and may become more widely available in 1-2 years

---

Important Reminders from Guidelines

✅ Multidisciplinary care is essential - Your treatment should involve input from medical oncology, surgery, radiation oncology, pathology, and palliative care specialists

✅ High-volume centers matter - Treatment decisions and complex cases should be evaluated at centers with expertise in pancreatic cancer

✅ CA 19-9 monitoring - This tumor marker can be tracked, but elevation alone (without other evidence of disease) is NOT a clear indication to start treatment

✅ Genetic counseling - If you test positive for inherited mutations (BRCA1/2, PALB2, etc.), genetic counseling is recommended for you and your family

---

Questions to Ask Your Oncology Team

1. Has molecular profiling been done on my tumor? Can I get a copy of the complete report?
2. Do I have any actionable mutations (like BRCA, KRAS, or others) that might make me eligible for targeted therapy?
3. Am I eligible for any clinical trials that might be appropriate for my specific mutation profile?
4. What is your recommended first-line treatment approach for my specific situation, and why?
5. Should I get a second opinion at a high-volume pancreatic cancer center?
6. What is the plan if my cancer progresses on the initial treatment?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.